[Immunotherapy of multiple recurring warts. Reassessment of the use of dinitrochlorobenzene (author's transl)].
The treatment of recalcitrant multiple verrucae vulgaris remains puzzling. Recent studies have demonstrated the relationship between the DNCB-induced cell mediated immunity and the resolution of warts. Our study consisted of 27 patients. Among them, 22 were sensitized to DNCB. A complete resolution of warts occurred in 81 p. 100 with minor side effects (pruritus, oedema and occasional bullae). However, the degradation of DNCB in dinitrophenol compounds in vivo, may be considered as a main drawback of this method. Since there is little information concerning the mutagenicity and toxicity of DNCB as yet, we suggest to prefer the use of other chemical compounds, such as dibutyl ester squarate, that act the same way as the DNCB does.
D000293:Adolescent; D000328:Adult; D002648:Child; D004137:Dinitrochlorobenzene / Q000627:therapeutic use*; D006229:Hand Dermatoses / Q000628:therapy; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007167:Immunotherapy; D007717:Knee; D007868:Leg Dermatoses / Q000628:therapy; D008875:Middle Aged; D009578:Nitrobenzenes / Q000627:therapeutic use*; D012008:Recurrence; D014860:Warts / Q000628:therapy*
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes
Traitement des verrues multiples et récidivantes par induction d'une hypersensibilité retardée. Etude critique de l'utilisation du dinitrochlorobenzène (DNCB).